No Detail Found!

Effectiveness of combination therapy versus monotherapy in multiple sclerosis: A systematic review and meta-analysis

Author(s)
Xiang Wang Institute of Basic Medicine, ChangChun University of Chinese Medicine,Changchun Jilin,China
Mingli Zhao Department of Rheumatology and Immunology, The Second Hospital of Dalian Medical University,Dalian Liaoning,China
Ping Liu Jilin Weather Modification Office,Changchun Jilin,China
Xiaoling Shang Institute of Basic Medicine, ChangChun University of Chinese Medicine,Changchun Jilin,China
Abstract
Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system (CNS) and the leading cause of non-traumatic neurological disability in young adults. Although current disease-modifying therapies (DMTs), such as interferon beta (IFNß) and glatiramer acetate, can reduce inflammation and delay disease progression, many patients continue to experience relapses. Given the complexity and variability of MS, combination therapy targeting multiple disease mechanisms is being explored as a more effective treatment approach. A comprehensive search of Medline and EMBASE databases was conducted using keywords related to MS, immunomodulatory agents, and combination therapy. Additional clinical trials were identified through the National MS Society database. A limited number of studies have investigated the use of IFNß with or without immunosuppressive agents. Preliminary findings suggest potential benefits of combination therapy, though evidence is constrained by small sample sizes, lack of randomization, and limited follow-up periods. Combination therapies may offer enhanced therapeutic effects in MS management. However, more rigorous and large-scale clinical trials are required to confirm their safety and efficacy.
Publication Details
Page(s) 1334-1346
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 38, Issue: 4, Year: 2025

Request the full text from PASTIC

Keywords
Central Nervous System (CNS), Combination therapy, Monotherapy, Multiple sclerosis (MS)
References
Arnal-García C,del Campo C,-Jorrin M,López-Real AM,Lema-Devesa C,Llopis N,Sanchez-de la Rosa N .2014 .Long-term effectiveness of glatiramer acetate in clinical practice conditions. J Clin Neurosci, 21(12) : 2212-2218.
Brown FS,Glasmacher SA,Kearns PK,MacDougall N,Hunt D,Connick P,Chandran S P .2020 .Systematic review of prediction models in relapsing remitting multiple sclerosis. PLoS One, 15(5) : e0233575.
Barzegar M,Najdaghi S,Afshari-Safavi A,Nehzat N,Mirmosayyeb O,Shaygannejad V .2021 .Early predictors of conversion to secondary progressive multiple sclerosis. Mult Scler Relat Disord., 54 : 103115.
Brück W,Gold R,Lund BT,Oreja-Guevara C,Prat A,Rudick R,Leist TP .2019 .Therapeutic decisions in multiple sclerosis: Moving beyond efficacy. J Neurol Sci, 405 : 116424.
Boziki MK,Mentis AFA,Shumilina M,Makshakov G,Kalnins G,Grigoriadis N G .2020 .The role of telemedicine in multiple sclerosis: A systematic review. J Telemed Telecare, 27(4) : 203-213.
Buron MD,Fernández Ó,Giovannoni G Gold R,Hemmer B,Montalban X,Oreja-Guevara C .2022 .A global survey of healthcare professionals' experiences and attitudes toward digital tools in multiple sclerosis care. Mult Scler Relat Disord, 63 : 103839.
Benedict RH,Zivadinov R .2011 .Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol, 7 : 332-342.
Costello F,Stüve O,Weber MS,Zamvil SS,Frohman E .2007 .Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice. Curr Opin Neurol, 20(3) : 281-285.
Chen C,Zhang E,Zhu C,Wei R,Ma L,Dong X,Liu Z X .2023 .Comparative efficacy and safety of diseasemodifying therapies in patients with relapsing multiple sclerosis: a systematic review and network metaanalysis. J Am Pharm Assoc, 63(1) : 8-22.
Cree BA,Arnold DL,Chataway J,Chitnis T,Fox RJ,Pozo Ramajo A,Lassmann H Ramajo A .2021 .Secondary progressive multiple sclerosis: New insights. Neurology, 97(8) : 378-388.
Caseby SCL,Woodhouse FA,Montgomery SM,Kroes M. A,Duddy ME .2022 .Transition to secondary progressive multiple sclerosis: The consequences for patients and healthcare systems, a healthcare professional survey. Health Sci Rep, 5(1) : e474.
Cross AH,Naismith RT .2014 .Established and novel disease-modifying treatments in multiple sclerosis. J Intern Med, 275(4) : 350-363.
Cree BAC,Bennett JL,Kim HJ,Weinshenker BG,Pittock SJ,Wingerchuk DM,Traboulsee AL DM .2021 .Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): A double-blind, randomised placebo-controlled phase 2/3 trial. The Lancet, 394(10206) : 1352-1363.
Cohen J. A.,Rae-Grant A. .2012 .Handbook of multiple sclerosis (5th ed. , : .
Cohan SL,Lucassen EB,Romba MC,Linch SN,Stern J NH,Bar-Or A,Piccio L A .2019 .DMTs in multiple sclerosis: Mechanisms of action and recent advances. Curr Neurol Neurosci Rep, 19 : 92.
Dobson R and Giovannoni G .2019 .Multiple sclerosis-a review. Eur J Neurol, 26(1) : 27-40.
Eisner E,Drake R,Lobban F,Bucci S,Emsley R,Barrowclough C .2018 .Comparing early signs and basic symptoms as methods for predicting psychotic relapse in clinical practice. Schizophr. Res., 192 : 124-130.
Filipi M and Jack S .2020 .Interferons in the treatment of multiple sclerosis: A clinical efficacy, safety, and tolerability update. Int J MS Care, 22(4) : 165-172.
Giovannoni G,Lang S,Wolff R,Duffy S,Hyde R,Kinter E,Kleijnen J .2020 .A systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis. Neurol Ther, 9 : 359-374.
Gabelić T,Barun B,Adamec I,Krbot Skorić M and Habek M I .2021 .Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis. Hum Vaccin Immunother, 17(11) : 4345-4362.
Hauser SL,Bar-Or A,Comi G,Giovannoni G,Hartung H P B,Kappos L B .2017 .Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New N Engl J Med, 376(3) : 221-234.
Kieseier BC,Stüve O .2011 .Combination therapy in MS-still a valid strategy. Nat Rev Neurol, 7(12) : 659-660.
Kleiter I,Ayzenberg I,Havla J,Lukas C,Penner IK,Stadelmann C,Linker RA C .2020 .The transitional phase of multiple sclerosis: Characterization and conceptual framework. Mult Scler Relat Disord, 44 : 102242.
La Mantia L,Di Pietrantonj C,Rovaris M,Rigon G,Berardo S,Vaona F,A F .2016 .Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev., 11(11) : CD009333.
Lang GGS,Wolff R,Duffy S,Wakeford RHEKC,Kleijnen MPSJ .2020 .A systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis. Mult Scler, 2 : 4-7.
Li R,Patterson KR,Bar-Or A .2018 .Reassessing B cell contributions in multiple sclerosis. Nature Immunology, 19 : 696-707.
Michel MC,Staskin D MC .2022 .Study designs for evaluation of combination treatment: Focus on individual patient benefit. Biomedicines, 10(2) : 270.
Panitch H Milo R .2011 .Combination therapy in multiple sclerosis. J Neuroimmunol, 231(1-2) : 23-31.
Mierau M,Schoels M,Gonda G,Fuchs J,Aletaha D,Smolen JS .2007 .Assessing remission in clinical practice. Rheumatol., 46(6) : 975-9.
Marrie RA,Reider N,Cohen J,Stuve O,Trojano M,Sørensen PS,Montalban X,Scler J .2015 .A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. , 21(3) : 263-281.
Macías Islas MÁ,Ciampi E .2019 .Assessment and management of cognitive impairment in multiple sclerosis: Current understanding and future directions. J Neurol, 266(1) : 35-44.
.2022 .Multiple sclerosis: Management (NICE Guideline NG220. , : .
Ontaneda D,Fox RJ .2015 .Progressive multiple sclerosis. Curr Opin Neurol, 28(3) : 237-243.
Stuart WH .2007 .Combination therapy for the treatment of multiple sclerosis: Challenges and opportunities. Curr Med Res Opin, 23(6) : 1199-1208.
Sorensen PS,Magyari M,Sellebjerg F M .2023 .An update on combination therapies for multiple sclerosis: where are we now?. Expert Rev Neurother, 23(12) : 1173-1187.
Saleem S,Anwar A,Fayyaz M,Anwer F and Anwar F M .2019 .An overview of therapeutic options in relapsingremitting multiple sclerosis. Cureus, 11(7) : .
Zajecka JM .2013 .Residual symptoms and relapse: mood, cognitive symptoms, and sleep disturbances. J Clin Psychiatry, 74(suppl 2) : 18130.
Sempik I,Dziadkowiak E,Moreira H,Zimny A,Pokryszko-Dragan A. .2024 .Primary progressive multiple sclerosis-a key to understanding and managing disease progression. Int J Mol Sci, 25(16) : 8751.
Schneider R and Oh J .2022 .Bruton's tyrosine kinase inhibition in multiple sclerosis. Curr Neurol Neurosci Rep, 22(11) : 721-734.
Solaro C,Trabucco E,Uccelli MM .2020 .Pain and multiple sclerosis: Pathophysiology and treatment. Curr Neurol Neurosci Rep, 20 : 58.
Tselis A,Khan O,Lisak RP .2007 .Glatiramer acetate in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat, 3(2) : 259-267.
Thompson AJ,Banwell BL,Barkhof F,Carroll WM,Coetzee T,Comi G,Cohen JA .2018 .Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol, 17(2) : 162-173.
Wingerchuk DM,Carter JL DM .2014 .Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. In Mayo Clinic Proceedings. Elsevier, 89(2) : 225-240.
Walton C,King R,Rechtman L,Kaye W,Leray E,Marrie RA,Wallin M .2020 .Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler, 26(14) : 1816-1821.
Wallin MT,Culpepper WJ,Campbell JD,Nelson LM,Langer-Gould A,Marrie RA,Kaye WE .2019 .The prevalence of MS in the United States: A populationbased estimate using health claims data. Neurology, 92(10) : e1029-e1040.
Ziemssen T,Rauer S,Stadelmann C,Henze T,Koehler J,Penner IK,Meuth S IK .2015 .Evaluation of study and patient characteristics of clinical studies in primary progressive multiple sclerosis: A systematic review. PLoS One, 10(9) : e0138243.
Zettl UK,Rommer PS,Aktas O,Wagner T,Richter J,Oschmann P,Hecker M .2023 .Interferon beta-1a sc at 25 years: A mainstay in the treatment of multiple sclerosis over the period of one generation. Expert Rev Clin Immunol, 19(11) : 1343-1359.
0

Citations

0

Downloads

71

Views